GLOBAL LIVER INSTITUTE
Global Liver Institute is proud to have been an early supporter of the President’s nominee, Dr. Monica Bertagnolli, as the Director of the National Institutes of Health (NIH). After nearly 2 years since Dr. Francis Collins left the position, the Senate on a bipartisan vote has now confirmed Dr. Bertagnolli as the new NIH Director.
(Washington, D.C., October 1, 2023) – Today marks the start of Liver Cancer Awareness Month, which will feature the monthlong #OctoberIs4Livers multifaceted campaign led by Global Liver Institute (GLI) to promote awareness of the disease, mark progress made, and identify key areas of global focus to make improvements for liver cancer patients. In addition to a comprehensive social media campaign, “Liver Cancer Lessons” education series, and featured conversations with expert guests and GLI CEO Donna R. Cryer, JD, partners around the world will host Open House events to inform and advocate to fight liver disease in their communities.
Washington, DC, September 27, 2023 – On Friday, September 22, 2023 President Joseph Biden signed the Securing the U.S. Organ Procurement and Transplantation Network (OPTN) Act into law – which was previously passed by Congress in July.
Global Liver Institute supports the selection of Jeanne M. Marrazzo, M.D., as director of the National Institute of Allergy and Infectious Diseases (NIAID) by the acting director of the NIH. Dr. Marrazzo is currently the director of the Division of Infectious Diseases at the University of Alabama at Birmingham and is a Fellow of the American College of Physicians and of the Infectious Diseases Society of America.
Global Liver Institute is pleased to nominate Julius M. Wilder MD, PhD to be a member of the NIDDK’s National Diabetes and Digestive and Kidney Diseases Advisory Council (NDDKAC).
Global Liver Institute recognizes the relationship between nonalcoholic fatty liver disease (NAFLD), its advanced form, nonalcoholic steatohepatitis (NASH), and obesity. Preventing liver disease is directly associated with treating and reducing obesity. Worldwide, NASH affects more than 148 million people and continues to become more prevalent each year.
Well-designed and well-conducted PPI studies elicit which attributes are important to patients, how important they are, and what trade-offs patients are willing to make.
GLI to Address Need for NAFLD/NASH Nomenclature Implementation Plan Since the joint medical society announcement of the change in nomenclature for NAFLD at the recent International Liver...
Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most common liver disease in the world – nonalcoholic fatty liver disease (NAFLD) – and it’s more severe form, nonalcoholic steatohepatitis (NASH).
Despite acknowledging OCA met the endpoint established by the FDA of reducing fibrosis by at least one stage, GIDAC voted against approval for treatment for NASH.
On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic Acid (OCA) for Non-Alcoholic Steatohepatitis: Effectiveness and Value. While the evidence presented for both drugs was deemed effective in fibrosis regression, ICER inconsistently voted to show that there was only a net health benefit in favor of resmetirom, being superior to lifestyle management alone, and not in OCA.
Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid for Non-Alcoholic Steatohepatitis: Effectiveness and Value.
